Drug intelligence / Profile preview

notoginsenoside Ft1

Development stage: Phase 2
Modality: Small Molecules
Administration: Oral

Overview

Notoginsenoside Ft1 is a saponin compound isolated from the leaves and stems of Panax notoginseng, a plant used in traditional Chinese medicine. It acts as an agonist of the G-protein coupled bile acid receptor TGR5 (Gpbar-1) and as an antagonist of the farnesoid X receptor (FXR). Through these dual actions, it promotes adipose tissue lipolysis, fat browning, and glucagon-like peptide-1 (GLP-1) secretion while modulating bile acid metabolism. Preclinical studies have shown that notoginsenoside Ft1 alleviates high-fat diet-induced obesity and insulin resistance in mice. The compound is being evaluated for its safety, tolerability, pharmacokinetics, and immunogenicity in healthy adult volunteers in a phase 1 clinical trial[3][4][7].

Other names: Ft1Ft-1Ft 1

Targets

GPBAR1FXR (Farnesoid x-activated receptor)

Beyond the preview

Go deeper on notoginsenoside Ft1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on notoginsenoside Ft1.

Explore the full profile